Valerie Orth studied biochemistry at Witten/Herdecke University and completed her PhD on function and targeting of platelet GPVI at the Julius Maximilians Unversity Würzburg (JMU). Since 2001, Valerie has been working in the field of platelet biology with a strong focus on adhesion receptors, antibody development, and experimental targeting approaches in animal models and human platelets. In 2005, she was appointed CEO of Emfret and has since been responsible for product development and commercial alignment of the company. Together with Bernhard Nieswandt, she is coordinating Emfret´s preclinical development programs, including the anti-GPVI lead candidate EMA601.